Lilly Asia Ventures

Lilly Asia Ventures is an independent life-sciences and healthcare venture fund that spun out from Eli Lilly's corporate venture arm in 2011 and is now among the most established biotech-focused investors in China's innovation market . The fund has built a track record across multiple financing stages, from angel and pre-A rounds in companies such as Yanming Biotech to leading or co-leading later rounds — it co-led the $55 million Series A in ProfoundBio alongside LYFE Capital in 2021 and participated in Cornerstone Robotics' RMB 500 million Series B that same year, with a follow-on investment in 2023 . Its portfolio also includes Shize Biotech, where it co-led the pre-A round with Qiming Venture Partners , and Singleron Biotechnologies, where it came in as an existing investor in a near-$100 million Series B . In 暗涌Waves' 2023 mapping of China's industrial investors, Lilly Asia Ventures was singled out as a "life sciences and healthcare CVC with industry leadership" and a key source of intelligence and product pipeline for Eli Lilly's own innovation .